person · Reporting owner
TAYTON-MARTIN HELEN KATRINA
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptimmune Therapeutics PLCADAP · Entity 9824 | Chief Business & Strgy Officer | January 15, 2024 | January 17, 2024 |
| Evaxion A/SEVAX · Entity 7553 | Chief Executive Officer | March 18, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptimmune Therapeutics PLC
Report date January 15, 2024 · Filed January 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.14 · Expires 2034-01-15 | Direct | 2,544,432 |
Reported balance
After 2024-01-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-15 · Grant · Acquired 2,544,432 · Balance 2,544,432 F1: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2: Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028. |
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2034-01-15 | Direct | 565,416 |
Reported balance
After 2024-01-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-15 · Grant · Acquired 565,416 · Balance 565,416 F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4: Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2: Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028.
F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4: Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028.
Evaxion A/S
Report date March 18, 2026 · Filed March 31, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy James Noble | 2,286,150 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 2,286,150 F1: Mr. Noble is Dr. Tayton-Martin's spouse. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.12 · Expires 2031-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance Not disclosed F2: Vesting is 1/36 per month over 36 months from the initial exercise date indicated. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Noble is Dr. Tayton-Martin's spouse.
F2: Vesting is 1/36 per month over 36 months from the initial exercise date indicated.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Trillium Therapeutics Inc.
Report date November 17, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.03 · Expires 2030-12-23 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-17 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
| Deferred Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-17 · Disposition to issuer · Disposed 498,294.287 · Balance 0 F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. F2: N/A |
Filing footnotes · ownership attribution and instrument terms
F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.
F2: N/A
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2024 Filed Jan 17, 2024 22:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 565,416 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004525 · tm243270-8_4seq1.xml · derivative · entry 2 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business & Strgy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,416 Underlying: Ordinary Shares · 565,416 shares Expires 2034-01-15 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028. Read SEC document |
| January 15, 2024 Filed Jan 17, 2024 22:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 2,544,432 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001104659-24-004525 · tm243270-8_4seq1.xml · derivative · entry 1 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business & Strgy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,544,432 Underlying: Ordinary Shares · 2,544,432 shares Expires 2034-01-15 F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 02:04 UTC | Adaptimmune Therapeutics PLC ADAP] · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 197,064 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004373 · tm231655-13_4seq1.xml · derivative · entry 3 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business & Strgy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,064 Underlying: Ordinary Shares · 197,064 shares Expires 2033-01-17 F5 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 02:04 UTC | Adaptimmune Therapeutics PLC ADAP] · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 314,256 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004373 · tm231655-13_4seq1.xml · derivative · entry 2 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business & Strgy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,256 Underlying: Ordinary Shares · 314,256 shares Expires 2033-01-17 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on January 17, 2025 and January 17, 2026, and 78,564 Ordinary Shares on January 17, 2027. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 02:04 UTC | Adaptimmune Therapeutics PLC ADAP] · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,407,072 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001104659-23-004373 · tm231655-13_4seq1.xml · derivative · entry 1 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business & Strgy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407,072 Underlying: Ordinary Shares · 1,407,072 shares Expires 2033-01-17 F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of U.S. $1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 02:03 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 314,256 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-004156 · tm221700-8_4seq1.xml · derivative · entry 2 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,256 Underlying: Ordinary Shares · 314,256 shares Expires 2032-01-12 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on January 12, 2024 and January 12, 2025, and 78,564 Ordinary Shares on January 12, 2026. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 02:03 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,407,072 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001104659-22-004156 · tm221700-8_4seq1.xml · derivative · entry 1 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407,072 Underlying: Ordinary Shares · 1,407,072 shares Expires 2032-01-12 F1 · derivative.exercise_price: The exercise price was converted from GBP0.44 based on an exchange rate of U.S. $1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:22 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerDeferred Share Unit · Derivative | 498,294.287 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-141738 · tm2133436-13_4seq1.xml · derivative · entry 2 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 498,294.287 shares Expires not disclosed F1 · derivative.exercise_price: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. F1 · price: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. F2 · derivative.expiration_date: N/A Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:22 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0001104659-21-141738 · tm2133436-13_4seq1.xml · derivative · entry 1 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 40,000 shares Expires 2030-12-23 F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 02:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | Exercise / conversionOrdinary Shares with a nominal value of GBP0.001 per share | 1,785,000 | $0.16 | $280,245.00 |
DisclosureSEC source: 0001104659-21-031733 · tm218630-1_4seq1.xml · nonDerivative · entry 1 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The ordinary shares whose purchase is reported on this line were obtained from the exercise of share options that were granted on March 20, 2015. The ordinary shares continue to be held by the Reporting Person. F2 · price: The price reported in Column 4 of $0.157 per ordinary share is derived from the option purchase price paid on March 3, 2021 of GBP0.112 per ordinary share. F3 · balance_after: The 1,800,000 ordinary shares reported in Column 5 include 1,785,000 ordinary shares reported in Column 4 as well as 15,000 ordinary shares held by the Reporting Person. The ordinary shares reported in Column 5 represent solely the ordinary shares beneficially owned by the Reporting Person. Additionally, the Reporting Person holds options covering an aggregate of 9,703,672 ordinary shares of the Issuer. Ordinary shares may be represented by American Depositary Shares (ADSs) with each ADS representing six ordinary shares. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 02:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 242,712 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-003131 · tm212800-3_4seq1.xml · derivative · entry 2 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,712 Underlying: Ordinary Shares · 242,712 shares Expires 2031-01-11 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on January 11, 2023 and January 11, 2024, and 60,678 Ordinary Shares on January 11, 2025. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 02:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,086,816 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-21-003131 · tm212800-3_4seq1.xml · derivative · entry 1 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,086,816 Underlying: Ordinary Shares · 1,086,816 shares Expires 2031-01-11 F1 · derivative.exercise_price: The exercise price was converted from GBP0.76 based on an exchange rate of U.S. $1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 01:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares | 200,000 | $8.74 | $1,748,180.00 |
DisclosureSEC source: 0001104659-20-090469 · a4.xml · nonDerivative · entry 1 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019. F3 · shares: The ADSs reported in this Column 4 represent solely those ADSs that were sold pursuant to a Rule 10b5-1 trading plan. Additionally, the reporting person holds 15,000 ordinary shares and share options covering an aggregate of 10,159,144 ordinary shares of the Issuer. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $8.50 to $9.34, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. Read SEC document |
| January 16, 2020 Filed Jan 18, 2020 02:35 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 280,896 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-005262 · a4.xml · derivative · entry 2 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,896 Underlying: Ordinary Shares · 280,896 shares Expires 2030-01-16 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S 1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 70,224 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 70,224 Ordinary Shares on January 16, 2022 and January 16, 2023, and 70,224 Ordinary Shares on January 16, 2024. Read SEC document |
| January 16, 2020 Filed Jan 18, 2020 02:35 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,257,744 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001104659-20-005262 · a4.xml · derivative · entry 1 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,257,744 Underlying: Ordinary Shares · 1,257,744 shares Expires 2030-01-16 F1 · derivative.exercise_price: The exercise price was converted from GBP0.57 based on an exchange rate of U.S$1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 314,436 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 26,202 Ordinary Shares on the sixteenth of each month from February 16, 2021 through December 16, 2023 and 26,238 Ordinary Shares on January 16, 2024. Read SEC document |
| January 13, 2020 Filed Jan 16, 2020 01:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares | 50,000 | $5.00 | $250,000.00 |
DisclosureSEC source: 0001104659-20-004422 · a4.xml · nonDerivative · entry 2 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019. F3 · price: These ADSs were sold in multiple transactions at a price of $5.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote. Read SEC document |
| January 13, 2020 Filed Jan 16, 2020 01:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares | 50,000 | $4.00 | $200,000.00 |
DisclosureSEC source: 0001104659-20-004422 · a4.xml · nonDerivative · entry 1 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019. F2 · price: These ADSs were sold in multiple transactions at a price of $4.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 02:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 224,724 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-001303 · a4.xml · derivative · entry 2 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,724 Underlying: Ordinary Shares · 224,724 shares Expires 2029-01-04 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 56,178 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 56,178 Ordinary Shares on January 4, 2021 and January 4, 2022, and 56,190 Ordinary Shares on January 4, 2023. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 02:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,006,224 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001104659-19-001303 · a4.xml · derivative · entry 1 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006,224 Underlying: Ordinary Shares · 1,006,224 shares Expires 2029-01-04 F1 · derivative.exercise_price: The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 251,556 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 20,958 Ordinary Shares on the fourth of each month from February 4, 2020 through December 2, 2022 and 21,138 Ordinary Shares on January 4, 2023. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 22:21 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 153,648 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-002678 · a4.xml · derivative · entry 2 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,648 Underlying: Ordinary Shares · 153,648 shares Expires 2028-01-12 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 38,412 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 38,412 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 22:21 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 687,984 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001104659-18-002678 · a4.xml · derivative · entry 1 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,984 Underlying: Ordinary Shares · 687,984 shares Expires 2028-01-12 F1 · derivative.exercise_price: The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 171,996 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 14,333 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 22:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 2,072,976 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001104659-17-002820 · a4.xml · derivative · entry 1 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,072,976 Underlying: Ordinary Shares · 2,072,976 shares Expires 2027-01-13 F1 · derivative.exercise_price: The exercise price was converted from GBP0.59 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 518,244 Ordinary Shares on January 13, 2018 and will be exercisable as to the remainder in monthly installments of 43,187 Ordinary Shares on the thirteenth of each month from February 13, 2018 through January 13, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.